September 2019 Trials of the Month

Type

Acronym

Study Title

Description

Participating Site(s) on COMET:

Breast

NATALEE

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hor-mone Receptor-positive, HER2-Negative Early Breast Cancer

  • HR+ Early Breast Cancer
  • Systemic Therapy
Sunnybrook Health Sciences Centre

GU

TRITON 3

A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

  • Metastatic Castration-Resistant Prostate Cancer
  • Systemic Therapy
London Health Sciences Centre

GI

 

AGENT

 

A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

  • Advanced Colorectal Cancer
  • Systemic Therapy
Sunnybrook Health Sciences Centre

HEME

CHIP

A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients >= 60 Receiving Cytotoxic Chemotherapy

  • Lymphoma Patients >= Age 60
  • Cohort Study
Sunnybrook Health Sciences Centre

LUNG

KEYNOTE-789

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants

  • Metastatic NSCLC
  • Systemic Therapy
Sunnybrook Health Sciences Centre
Gyne

 

 

MK-7339-001 / KEYLYNK-001

 

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC)

  • Advanced Epithelial Ovarian Cancer
  • Systemic Therapy
Kingston General Hospital

Any

SMARTCare

A Multi-Centre, Randomized Controlled Trial of Self-Management and Activation to Reduce Treatment-Related Toxicities in Patients Receiving Adjuvant or First-Line Metastatic Oral or Systematic Therapy for Colorectal, Lymphoma or Lung Cancer

  • Adjuvant or Metastatic Colorectal, Lymphoma or Lung Cancer
  • Supportive Care
Royal Victoria Regional Health Centre